Allergic rhinoconjunctivitis and/or allergic asthma against birch pollen J30.1 J45.0 H10.1
Conditions
Interventions
Group 1: Study-related taking of blood samples and of nasal discharge for analysis, no further intervention.
Sponsors
Klinik für Dermatologie und Allergologie
Philipps-Universität Marburg
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Rhinoconjunctivitis allergica or allergic asthma with maximal symptoms in the springtime. Immediate-type sensitisation against birch pollen in clincial tests: positive skin prick test or intracutaneous test against birch pollen. Positive nasal provocation against birch pollen. Sensitisation against birch pollen (and the major allergen Bet v 1) detectable in vitro. Specific IgE at least of CAP-class 2 (against the classical birch pollen allergen) and at least of CAP-class 1 against recombinant Bet v 1. Signed declaration of consent.
Exclusion criteria
Exclusion criteria: Contraindication against specific immunotherapy. Patients unable to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Induction of regulatory T cells; Taking of blood samples before and 1, 3, 6, 12, 18, 24, 30, 36, 42, 48 months after initiation of SIT; Determination of allergen-specific Treg and Teff frequencies as well as quantification of cytokines and specific antibodies | — |
Countries
Germany
Contacts
Public ContactWolfgang Pfützner
Klinik für Dermatologie und Allergologie
Outcome results
None listed